On September 26, 2025, SAB Biotherapeutics, Inc. approved amendments to increase the equity incentive plan by 24.18 million shares, totaling 31.93 million, and allowed the issuance of over 19.99% of common stock conversion from Series B Preferred Stock. The approval votes were 5.50 million for and 515 thousand against for the stock conversion proposal, and 5.09 million for and 951 thousand against for the equity plan amendment.